



## Yumanity Therapeutics to Present at the 2021 RBC Capital Markets Global Healthcare Conference

May 12, 2021

BOSTON, May 12, 2021 (GLOBE NEWSWIRE) -- Yumanity Therapeutics (NASDAQ: YMTX), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that Richard Peters, M.D., Ph.D., President and Chief Executive Officer, will present at the 2021 RBC Capital Markets Global Healthcare Conference on Wednesday, May 19, 2021, at 5:25 p.m. EDT.

A live audio webcast of the presentation can be accessed through the Events section of the Company's website at [yumanity.com/events](https://yumanity.com/events). An archived replay of the webcast will be available on the Company's website following the live presentation.

### About Yumanity Therapeutics

Yumanity Therapeutics is a clinical-stage biopharmaceutical company dedicated to accelerating the revolution in the treatment of neurodegenerative diseases through its scientific foundation and drug discovery platform. The Company's most advanced product candidate, YTX-7739, is currently in Phase 1 clinical development for Parkinson's disease. Yumanity's drug discovery platform enables the Company to rapidly screen for potential disease-modifying therapies by overcoming the toxicity of misfolded proteins associated with neurodegenerative diseases. Yumanity's pipeline consists of additional programs focused on Lewy body dementia, multi-system atrophy, amyotrophic lateral sclerosis (ALS or Lou Gehrig's disease), frontotemporal lobar dementia (FTLD), and Alzheimer's disease. For more information, please visit [www.yumanity.com](https://www.yumanity.com).

### Investors:

Burns McClellan, Inc.  
Lee Roth  
[lroth@burnsmc.com](mailto:lroth@burnsmc.com)  
(212) 213-0006

### Media:

Burns McClellan, Inc.  
Ryo Imai / Robert Flamm, Ph.D.  
[rimai@burnsmc.com](mailto:rimai@burnsmc.com) / [rflamm@burnsmc.com](mailto:rflamm@burnsmc.com)  
(212) 213-0006



Source: Yumanity Therapeutics Inc